Biognosys Announces New Release of Spectronaut™
15.6.2021 09:00:00 EEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for life sciences research and development, announced today the launch of Spectronaut 15. The software provides fast, robust, and seamless data analysis for mass spectrometry (MS) based data-independent acquisition (DIA) proteomics. Thus, Spectronaut enables the investigation of protein expression, function, and structure across all major biological species and sample types.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210614005013/en/
Spectronaut - The gold standard for DIA proteomics analysis (Graphic: Business Wire)
Spectronaut is a commercial software for industry and academia and is also used as part of Biognosys' discovery proteomics contract research services. In conjunction with the company's proprietary, patented Hyper Reaction Monitoring (HRM™) technology, Spectronaut enables reproducible and precise quantification of up to 10,000 proteins in large-scale studies. The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for R&D and clinical research.
Since its first release in 2003, Spectronaut is continuously improving and always supports the newest technologies in data acquisition. The 15th generation of the software comes with an array of novel features and updates, such as:
- Significant improvements to directDIA, the industry-leading library-free DIA workflow
- A more comprehensive toolset for post-translational modification (PTM) analysis
- Improved deep learning augmentation for immunopeptidomics and ion mobility data analysis
- Powerful data visualization in an intuitive user interface
"With this new Spectronaut release, we offer our software users and service customers once more a higher level of performance, user experience, and insights to support their discovery proteomics research", said Biognosys CTO Lukas Reiter, PhD.
Spectronaut lead developer Oliver M. Bernhardt will share more details on the new features during the Spectronaut 15 launch webinar , Expand Biological insights with DIA Proteomics , held today at 5 PM CEST. Beyond that, Guest speaker Andreas-David Brunner will present a robust and scalable single-cell DIA proteomics workflow using ion mobility technology (dia-PASEF), developed at the Max Planck Institute of Biochemistry (Matthias Mann Lab).
Spectronaut 15 is fully vendor-independent and compatible with proteomics data acquired on instruments of all major mass spectrometer vendors.
Gary Kruppa, Vice President, Proteomics at Bruker Daltonics:
"Spectronaut has made it possible to implement our breakthrough dia-PASEF technology in many of our customer's facilities. With the latest Spectronaut release, the support for our ion mobility technology has seen a significant improvement, and we are looking forward to continuing our collaboration with Biognosys to maintain Spectronaut as a key solution for Bruker's DIA workflows."
Andreas Huhmer, Director Marketing, Mass Spectrometry Solutions at Thermo Fisher Scientific:
"Biognosys' Spectronaut is our software of choice to analyze DIA data in internal projects, including acquisition method development. Of course, it is also the solution we strongly recommend to our customers. Spectronaut has always been at the forefront when it comes to supporting our technology, and its ease of use and versatility makes it the best partner for DIA data analysis."
For more information about Spectronaut, including details about free trials and pricing, please visit biognosys.com/spectronaut.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys' unique, patented technologies utilize high-resolution mass spectrometry for the quantification of thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at www.biognosys.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005013/en/
Contact information
Lukas Reiter, PhD
Chief Technology Officer
Phone +41 (0) 44 738 20 40
lukas.reiter@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Union of Kansai Governments: Kansai Deep Tech Ecosystem Gains Global Visibility31.3.2026 03:00:00 EEST | Press release
The Union of Kansai Governments has refreshed the Kansai Startup Ecosystem portal, strengthening the region’s global communication platform for startups and deep tech. At the same time, the “DeepTech Frontier Kansai” website has also been updated, further enhancing international visibility for Kansai’s rapidly growing deep tech ecosystem. Kansai’s startup ecosystem has demonstrated steady growth in recent years. The ecosystem’s total value expanded from USD 2.68 billion in 2023 to USD 3.23 billion in 2025. In addition, Kansai rose 20 places in the Global Startup Ecosystem Ranking (GSER) published by Startup Genome, climbing from 99th in 2023 to 79th in 2025, and early-stage funding reached USD 124 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330459051/en/ Kansai’s Strength in Deep Tech Kansai represents a rare ecosystem where fundamental research and industrial application coexist in close geographic proximity,
Klarna Payments Now Available at B-Parts, Europe's Largest Automotive Parts Website30.3.2026 22:51:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, is joining forces with B-Parts, a leading online retailer of used and original car parts, to offer consumers greater flexibility, convenience, choice and control at the point of payments, with no interest or hidden fees. Through Klarna’s interest-free installment payments, B-Parts customers will benefit from greater flexibility and control over their finances. Klarna also ensures a secure shopping experience thanks to its buyer protection scheme, as well as a range of features such as cashback and deals. "We continue to grow locally, with an increasing number of brands across different sectors recognising the enormous advantage of offering their customers more payment options, those that make for a more convenient and seamless checkout experience," explains Inês Fiúza Marques, Country Manager of Klarna in Portugal. "It's fantastic to have B-Parts on board, and it shows just how broadly our solutions are being embraced." Ma
Office of His Highness Sheikh Hamdan Bin Ahmed Al Maktoum Holdings & Gatbits IT Infrastructure Announce Launch of GTBS Digital Ecosystem; Mainnet Set for April 202630.3.2026 21:30:00 EEST | Press release
The Office of His Highness Sheikh Hamdan Bin Ahmed Al Maktoum Holdings, in collaboration with Gatbits IT Infrastructure, has officially announced the launch of the GTBS Digital Ecosystem, marking a significant step forward in the global Web3 space. The announcement follows the successful launch of the native GTBS Coin on December 25, with the ecosystem’s mainnet scheduled to go live in April 2026. GTBS represents a full-stack Web3 ecosystem integrating blockchain, artificial intelligence, decentralized finance (DeFi), entertainment, gaming, media, and cloud infrastructure into a unified platform. Built on the philosophy of “All Commitment On Time,” the ecosystem focuses on delivering reliability, scalability, and real-world utility. Designed as a comprehensive digital infrastructure, GTBS goes beyond standalone crypto platforms by offering an integrated environment for users, developers, creators, and enterprises. Its proprietary Layer-1 blockchain powers seamless interaction across se
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom